|
Administration
May be taken with or without food.
|
|
Special Precautions
Patient with diabetes mellitus, G6PD deficiency, haemochromatosis, history of renal stones (e.g. oxalate kidney stones), predisposition to recurrent renal calculi. Renal impairment. Children (<2 years of age) and elderly. Pregnancy and lactation. Monitoring Parameters Monitor renal function (patient with a predisposition to oxalate nephropathy), haemoglobin, and blood counts (G6PD deficient patient).
|
|
Adverse Reactions
Significant: Acute or chronic oxalate nephropathy (prolonged use; large doses).
Gastrointestinal disorders: Diarrhoea, nausea, vomiting, heartburn.
General disorders and administration site conditions: Fatigue, pain at the inj site.
Nervous system disorders: Dizziness, headache.
Vascular disorders: Flushing.
|
|
Drug Interactions
Increased absorption of Fe. Increased excretion of Fe with desferrioxamine. Induced tissue desaturation with aspirin, nicotine, Fe, phenytoin, tetracycline, estrogen in oral contraceptives, some appetite suppressants and anticonvulsants. May increase the absorption of Al-containing antacids. May diminish the activity of anticoagulants (e.g. warfarin). May increase the serum concentration of estrogen derivatives. May decrease the serum concentration of amphetamines.
|
|
CIMS Class
|
|
ATC Classification
S01XA15 - ascorbic acid ; Belongs to the class of other ophthalmologicals.
G01AD03 - ascorbic acid ; Belongs to the class of organic acid antiinfectives. Used in the treatment of gynecological infections. |
Sign Out
